Clinical Trial: NCT02227251
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Karyopharm Therapeutics Inc |
| Information Provided By: | Karyopharm Therapeutics Inc |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Official Title
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions
Diffuse Large B-cell Lymphoma
Intervention / Treatment
- Drug: Selinexor
- Drug: Selinexor
- Drug: Selinexor
Other Study ID Numbers
- KCP-330-009
- 2014-001977-15
- 2014
Start Date (Actual)
2014-11
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
244
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Karyopharm Therapeutics Inc |
| Information Provided By: | Karyopharm Therapeutics Inc |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Official Title
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions
Diffuse Large B-cell Lymphoma
Intervention / Treatment
- Drug: Selinexor
- Drug: Selinexor
- Drug: Selinexor
Other Study ID Numbers
- KCP-330-009
- 2014-001977-15
- 2014
Start Date (Actual)
2014-11
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
244
Study Type
Interventional
Phase
Phase 2